Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P25189
UPID:
MYP0_HUMAN
Alternative names:
Myelin peripheral protein; Myelin protein zero
Alternative UPACC:
P25189; Q16072; Q5VTH4; Q92677; Q9BR67
Background:
Myelin protein P0, also known as Myelin peripheral protein, plays a pivotal role in the peripheral nervous system as an adhesion molecule. It is essential for the normal myelination process, facilitating the adhesion between adjacent myelin wraps and driving myelin compaction.
Therapeutic significance:
Given its crucial role in myelination, Myelin protein P0 is linked to several neuropathies, including various forms of Charcot-Marie-Tooth disease and congenital hypomyelinating neuropathy. Understanding the role of Myelin protein P0 could open doors to potential therapeutic strategies for these debilitating conditions.